hotspot -WSS

hotspot

author：comprehensive 2025-09-29 14:23:41 - browse：8883

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： DeepMind touts AlphaFold's new skills as protein folding AI models face off

WSS

Amylyx ALS drug fails large clinical trial

Readout LOUD podcast: ESMO highlights & Roivant's big deal

RSV shot was 90% effective at preventing hospitalizations in kids

Key Senate panel to consider PBM, drug pricing reform package

All of Us, NIH's precision medicine initiative, gets a big boost

How neuroscience research could help beat back brain cancer

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

What it’s like to watch children die of measles

Heart attack and stroke risk calculators need revising

Travis Kelce and the trap of celebrity vaccine endorsements

Malaria cases in Florida and Texas: Here’s what you need to know

Gene therapy’s promise and the high cost of hope

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Amylyx ALS drug fails large clinical trial

Duchenne breakthrough therapy leaves behind pioneering families

Air quality improving but still lags in Black, Hispanic communities

knowledge

Brain injuries and the importance of a second opinion

Humans aren't the only ones with an imagination. Rats have it too

Bill would allow buprenorphine prescription for addiction via telehealth

The Readout: Amylyx, Alumis, and Lundbeck drug updates

With psoriasis trial ahead, Alumis raises $259 million

Medicare proceeds with plan to claw back hospital funds

hotspot

Wikipedia

focus

hotspot